SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 13.54 HKD | +0.15% |
|
+1.35% | -20.35% |
| 05-15 | Fosun Pharma Unit Fosun Health to Receive Capital Injection from Foshan Chanxi City Investment | MT |
| 05-15 | China Approves Clinical Trials For Breast Cancer Drugs | MT |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The group shows a rather high level of debt in proportion to its EBITDA.
- The company is highly valued given the cash flows generated by its activity.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
Ratings chart - Surperformance
Sector: Pharmaceuticals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -20.35% | 7.94B | - | ||
| +34.35% | 693B | C+ | ||
| +29.39% | 584B | B | ||
| -3.49% | 372B | C+ | ||
| +20.15% | 332B | B- | ||
| +6.19% | 294B | C+ | ||
| +14.11% | 239B | B+ | ||
| -3.03% | 211B | A+ | ||
| +10.02% | 210B | B- | ||
| +9.21% | 168B | C+ |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- 600196 Stock
- 2196 Stock
- Ratings Shanghai Fosun Pharmaceutical (Group) Co., Ltd.